P450; HLM, human liver microsomes; HIM, human intestinal microsomes; TLC, thin layer chromatography; 2D-TLC, two-dimensional thin layer chromatography; HPLC, high performance liquid chromatography, K m , apparent Michaelis-Menten constant; V max , apparent maximal initial disappearance velocity; CL int ; intrinsic clearance.; CL int.cDNA-X , intrinsic clearance for the formation of each metabolite obtained from recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4; RAF, relative activity factor; CL int.HLM-CYP-X , intrinsic clearance for the formation of each metabolite in HLM calculated from data in recombinant CYPs and RAF values; CL int.HLM-total , total intrinsic clearance for the formation of each metabolite in HLM expressed as the sum of the formation clearance with each CYP form; SKF-525A, proadifen-hydrochloride. NE-152＋163mix, the mixture of the mixtures of two hydoxylated metabolites, NE-152 and NE-163.
Introduction

NE-100
( N, N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]-ethyl-amine-monohydrochloride) is a novel sigma ligand that has been developed as a therapeutic drug for treating subjects with schizophrenia. 1, 2) We have reported that the clinical eŠective level (concentration) of NE-100 required for therapy of schizophrenic subjects might be low due to high a‹nity for sigma receptor. 3) In pre-clinical pharmacokinetic experiments, NE-100 rapidly disappeared from the in vitro rat intestinal loop and bioavailability of NE-100 after oral administration to rats was low (unpublished data). Metabolites of NE-100 were detected only as high polarity compounds in rat plasma and urine, and dog plasma. Primary metabolites of NE-100 and their metabolizing enzymes remained to be identiˆed in rats and humans. In our previous study using various recombinant CYP forms, NE-100 metabolism was shown to be mainly mediated by multiple CYP forms, CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. Based on the kinetic study, NE-100 metabolism by human liver microsomes (HLM) was catalyzed by CYP2D6 (high a‹nity) and other CYPs (low-a‹nity), but the metabolism by human intestinal microsomes (HIM) was mainly catalyzed by CYP3A4 (low a‹nity). These data suggested that CYP2D6 as a high-a‹nity enzyme and CYP3A4 as a low-a‹nity enzyme play an important role in NE-100 disappearance in HLM and in HIM, respectively.
3) The contribution of these CYP forms for primary metabolites of NE-100 remained to be quantitatively predicted. CYP2D6 accounts for only 2z of the total CYP content in the liver, but it is involved in 30z metabolism of clinically relevant drugs. [4] [5] [6] In addition, CYP2D6 as well as CYP2C19 has genetic polymorphism, which may bring a serious eŠect on pharmacokinetic, pharmacodynamic and toxicologic behavior. [7] [8] [9] [10] CYP3A4 is the most abundant form among all known CYP forms and accounts for about 20-30z of the total P450 in the human liver and it participates in oxidative biotransformation of over 50z of commercially relevant drugs. [4] [5] [6] 11) In recent studies, intestinal metabolism has been attracting attention regarding thê rst pass metabolism of orally administered drugs. 12) Various drug-metabolizing enzymes have been detected in the small intestinal mucosa. In particular, of the CYP forms involved in drug metabolism, CYP3A4 is the most abundant form and the expression is about 70z of the total CYP content in intestinal microsomes. 11, 13) Therefore a number of drugs metabolized by CYP3A4 have low bioavailability after oral administration, for example felodipine, verapamil, saquinavir, cyclosporine, midazolam, and terfenadine. 14) Cyclosporin A is metabolized in the small intestine at a rate of 50z of dose administered orally. 15) In addition, grapefruit components (furanocumarion) interact with drugs metabolized by CYP3A4 in the small intestine. [16] [17] [18] Therefore, identiˆcation of major CYP form(s) involved in the metabolism of drugs in HLM and HIM is very important for the development of novel drugs. In particular, the contribution rate of CYP forms catalyzing the formation of drug metabolites is required to predict in advance clinical drug-drug interactions.
The objective of this study was to identify major CYP forms involved in the formation of primary NE-100 metabolites in HLM and HIM and to predict the contribution rate of CYP forms to the formation of individual metabolites.
Materials and Methods
Chemicals and reagents: NE-100 hydrochloride and its metabolites, ) . Furafylline, sulfaphenazole, S-mephenytoin, quinidine and ketoconazole, and 6-hydroxychlorzoxazone were purchased from Ultraˆne Chemicals Co. (Manchester, UK). Acetaminophen, 7-hydroxycoumarin, 7-ethoxy-4-tri‰uoro-methylcoumarin, dextromethorphan, dextrorphan, chlorzoxazone, testosterone, lauric acid, 12-hydroxydodecanoic acid, troleandomycine, omeprazole and lansoprazole were purchased from Sigma-Aldrich (St. Louis, MO, USA). 5-Hydroxy-omeprazole and proadifen hydrochloride (SKF-525A) were from Fujisawa Astra Co. (Osaka, Japan) and from Funakoshi Co. Ltd. (Tokyo, Japan), respectively. 6 bHydroxytestosterone was from Sumika Chemical Analysis Service (Osaka, Japan). All other chemicals and solvents used were of the highest quality commercially available. 7-Hydroxy-4-tri‰uoro-methyl-coumarin, monoclonal anti-CYP2D6 and CYP3A4 antibodies were obtained from BD Gentest Corporation (Woburn, MA, USA). Antiserum against rat CYP2C13 and human CYP2D6 were from Daiichi Pure Chemicals (Tokyo, Japan).
Enzyme: Pooled human liver microsomes (HLM; H161-lot.3) were obtained from BD Gentest Corporation (Woburn, MA, USA). Individual human livers were from SRI International Toxicology Laboratory (Menlo Park, CA, USA) and the Department of Anatomic Pathology (School of Medicine, Tohoku University, Sendai). Experiments on human livers were approved by the Tohoku University Ethics Committee. Microsomes of a human B lymphoblast cells expressing recombinant human CYP enzymes (i.e. CYP1A2, 2C9-Arg, 2C19, 2D6*1-Val and 3A4) were purchased from BD Gentest Corporation (Woburn, MA, USA). Human intestinal microsomes were from Tissue Transformation Technologies (Edison, New Jersey, USA).
Determination of primary NE-100 metabolites in human liver microsomes: The metabolic reaction was performed by incubating with HLM equivalent to 1 mg protein W mL and 20 mM NE-100 for 5 min in the presence of the NADPH-generating system. After incubation, the metabolites were separated by twodimensional thin layer chromatography (2D-TLC) (1st.; CHCl3 W Hexane W Methanol W Acetic acid ＝ 6 W 4 W 2 W 0.4, 2nd; Toluene W Ether W Methanol W NH4OH＝40 W 60 W 10 W 3, HPTLC plate; kieselgel 60F254, Merck Co. Ltd, Whitehouse Station, NJ, USA) and were puriˆed using a radiometric high performance liquid chromatography (HPLC) analysis. The HPLC system consisted of a model 305 pump (Gilson, France), model 231 auto sampler (Gilson), model 203UV detector (Gilson), column oven (Anachem), GINA system controller (Raytest, Germany), Ramona LS-90 radioactive detector (Raytest), data processor (Sony, Tokyo, Japan) and an analytical column (Capcell pak phenyl SG120, 5 mM, 4.5 mm i.d.×150 mm, Shiseido, Tokyo, Japan). For puriˆcation, the mobile phase A and B were 0.1 M ammonium acetate (pH 4.0) and acetonitrile (gradient program: 0¿30 min, 0¿40z B (linear gradient); 30¿40 min, 40z B; 40¿60 min, 0z B), respectively. The ‰ow rate was delivered at 1.0 mL W min. The column temperature was maintained at 409 C. Each metabolite in HLM was identiˆed by Rf (ratio of the distance traveled by the center of the solute zone to the distance traveled by the solvent front) value and the retention time of the metabolites compared with those of synthetic standard by co-chromatography using 2D-TLC and HPLC analysis.
Assay of metabolites: The reaction mixtures including methanol were shaken and centrifuged at 3,000 rpm for 10 min, then the supernatant was evaporated to dryness then re-dissolved with methanol. To separate the metabolites of NE-100 in the sample, 2D-TLC analysis was done using the TLC plate and the solvent system as described above. Radioluminography, BAS2000 system (Fuji-ˆlm, Tokyo, Japan), was used to quantify these metabolites.
Kinetic study of NE-100 metabolism by human liver and intestinal microsomes: Kinetic studies for the formation of NE-100 metabolites were done using HLM and HIM. Incubation medium contained 0.20 mg W mL HLM or 0.25 mg W mL HIM and 50 mM potassium phosphate buŠer (pH 7.4), an NADPH-generating system (0.4 mM NADP ＋ , 8 mM glucose 6-phosphate, 8 mM MgCl2, 0.5 IUW mL of glucose 6-phosphate dehydrogenase) and various concentrations of NE-100, in aˆnal volume of 500 mL (for HLM) or 250 mL (for HIM). For HLM, after preincubation at 379 C for 5 min, the reaction was initiated by adding NE-100 at concentrations ranging from 0.05 to 20 mM for 0.167-30 min and was terminated by adding 1 ml of methanol. For HIM, after preincubation, the reaction was initiated by adding NE-100 at concentrations ranging from 0.2 to 200 mM for 2-30 min and was stopped as described above. Linearity of the formation activity for each metabolite, with respect to the concentration of microsomes and the incubation time, was assessed by leastsquares linear regression using Microsoft Excel.
Kinetic study of NE-100 metabolism by recombinant human CYP forms: Kinetic studies for the formation of each metabolite of NE-100 were done using recombinant CYPs microsomes (CYP1A2, 2C9-Arg, 2C19, 2D6-Val and 3A4). The reaction contained recombinant CYP2D6, CYP2C9 or CYP3A4 microsomal proteins of 0.20, 0.46 or 0.43 mg W mL, respectively, was initiated by adding NE-100 at concentrations ranging from 0.05 to 20 mM. Incubation times are for 0.167-30 min in CYP2D6 and for 0.167-30 min in CYP2C9 and CYP3A4. Other reaction conditions were the same as described for HLM.
Correlation study: NE-100 metabolism was assessed in incubation mixtures containing 0.1 mg W mL microsomes, the NADPH-generating system and 1 mM NE-100 in 50 mM potassium phosphate buŠer (pH 7.4) for 5 min. Formation activities of each metabolite in HLM were compared with phenacetin O-deethylation (CYP1A1 W 2), coumarin 7-hydroxylation (CYP2A6), 7-ethoxy 4-tri‰uomethyl coumarin O-deethlation (CYP2B6), omeprazole 5-hydroxylation (CYP2C19), dextrometrophan 6-hydroxylation (CYP2D6), chlorzoxazone 6-hydroxylation (CYP2E1), testosterone 6 bhydroxylation (CYP3A4) and lauric acid v-hydroxylation activity (CYP4A11), using microsomes obtained from 28 individual human livers as described previously. 3) Immunoinhibition study: The inhibitory eŠects of monoclonal anti-CYP2D6 and anti-CYP3A4 antibodies on the formation of the metabolite were assessed using HLM. After preincubation with HLM (0.2 mg W mL) and an antibody on ice for 15 min, the reaction was carried out by adding NE-100 (0.1, 1 and 10 mM) at 379 C for 5, 10 and 15 min, respectively. For HIM, a monoclonal anti-CYP3A4 antibody or anti-CYP2C13 serum were preincubated with HIM (0.25 mg W mL) on ice for 15 min, or at room temperature for 30 min, respectively. The reactions were carried out by addition of NE-100 (10 and 200 mM) at 379 C for 20 and 30 min, respectively. All reactions were stopped using 1 mL of methanol.
Chemical inhibition study: Inhibitory eŠects of selective inhibitors for CYP forms on each formation of metabolites of NE-100 in HLM and HIM were undertaken with 0.1 mM, 10 mM (for HLM) and 0.2 mM, 10 mM, 200 mM NE-100 (for HIM). Concentration of inhibitors used and reaction procedures were based on our descriptions given elsewhere. 3) Data analysis: Assuming one-or two-enzyme models as described by Nakajima et al., 19) kinetic data of enzyme, Km and Vmax values (Km1 and Vmax1 for high a‹nity component, Km2 and Vmax2 for low a‹nity component) for formation of each metabolite were estimated using residual analysis on Eadie-Hofstee plots based on visual inspection. Intrinsic clearance (CLint) was calculated as ratio of the Vmax to the Km. Correlation between the formation activity of each metabolite and the metabolite formation activities of the respective CYP forms-speciˆc substrates were examined by leastsquares linear regression analysis. The statistical signiˆcance of diŠerences between the control and inhibitor treatments was determined by Dunnett's test (SAS system for windows, ver 6.1, SAS Institute Inc., Cary, NC, USA). A p-valueº0.05 was considered to be statistically signiˆcant.
Relative contribution rate of each CYP form to formation activity of each metabolite in HLM:
1) Rate of contribution under linear conditions for the formation of metabolites
The contribution rates of each CYP form to the formation of each metabolite were estimated based on kinetic data obtained from recombinant CYP forms, using the RAF proposed by Crespi. 20) The intrinsic clearances (CL int.HLM-CYP-X ) for the formation of each metabolite in HLM were calculated as follows:
where CLint.cDNA-X and RAFCYP-X are intrinsic clearance for the formation of each metabolite obtained from recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and RAF values for each CYP form, respectively. The total intrinsic clearance for the formation (CLint.HLM-total) of each metabolite in HLM was expressed as the sum of the CL int.HLM-CYP-X for each CYP form. The contribution rates of each CYP form to the CLint.HLM-total for the formation of each metabolite were estimated as the percent of CLint.HLM-CYP-X to CLint.HLM-total.
2) Relative rate of contribution of each CYP form depending on substrate concentration
The relative rates of contribution of each CYP form to the formation activity of each metabolite in HLM, depending on substrate concentration, were predicted using a kinetic parameter (K m , V max ) from recombinant CYP forms and RAF values. The formation velocity of the metabolite (VHLM-CYP-X) for each CYP form in HLM at various substrate concentrations was calculated as follows:
where S, Km.cDNA-CYP-X, Vmax.cDNA-CYP-X and RAFCYP-X are substrate concentration, a‹nity constants, the maximum formation velocities of each metabolite for each recombinant CYP microsome and RAF values for each CYP, respectively. The total formation velocities (VHLM-total) of each metabolite at various substrate concentrations in HLM are expressed as the sum of the VHLM-CYP-X for each recombinant CYP form. The contribution rates of each CYP form to the formation velocity of each metabolite in HLM at various substrate concentrations were estimated as the percent of VHLM-CYP-X to VHLM-total.
Results
Kinetic study of NE-100 metabolism by human liver and intestinal microsomes: In the co-chromatography using 2D-TLC and HPLC analysis, the metabolites detected in a reaction sample with HLM corresponded to the authentic synthesized standards in Rf values on 2D-TLC and retention time on HPLC chromatograms. Possible metabolic pathways of NE-100 in HLM were N-depropylation (NE-098), hydroxylation of the phenyl ring portion (NE-152 and NE-163) and O-demethylation (NE-125) (Fig. 1) . As NE-152 and NE-163 could not be quantitatively separated by the TLC method in this experiment, these metabolites were measured as a mixture of NE-152 and NE-163 and expressed as NE-152＋ 163mix.
Eadie-Hofstee plots for NE-098, NE-152＋163mix and NE-125 formations in HLM, and HIM are shown in Fig. 2 . The plots for NE-098 and NE-152＋163mix formations in HLM showed biphasic curves (high-and low-a‹nity components), while plots for NE-125 formation showed a monophasic curve. Km1 (high a‹nity component) values of NE-098 and NE-152＋163mix formations were 110.1 and 45.6 times smaller than Km2 (low a‹nity component) values of those metabolite formations, respectively ( Table 1) . The Km value (0.07 mM) of NE-125 formation was similar to the Km2 values of NE-098 and NE-152＋163mix formations (0.16 mM and 0.14 mM). Intrinsic clearance (CLint-HLM) of these metabolites in HLM was the largest in the formation of NE-125, followed by NE-152＋163mix and NE-098 formations. In HIM, NE-100 was mainly metabolized to NE-098 and NE152＋163mix. Eadie Hofstee plot for NE-098 was monophasic while that for NE152＋163mix was biphasic. Intrinsic clearance (CL int-HIM ) of NE-098 formation was 3.9 times larger than that in case of the NE-152＋163mix. CLint-HIMs of these metabolites in HIM were 3.2 and 14.9 times smaller than those in HLM, respectively.
Correlation study: Correlation between activities of NE-098, NE-152＋163mix or NE-125 formation and speciˆc CYP substrate in 28 liver samples is shown in Table 2 . Among the speciˆc substrate activities Assuming one-or two-enzyme models as shown by Nakajima et al., 19) kinetic data on enzyme, K m and V max values (K m1 and V max1 for high a‹nity component, K m2 and V max2 for low a‹nity component) for formation of each metabolite were estimated using residual analysis on Eadie-Hofstee plots based on visual inspection. For NE-100 metabolism in liver, K m1 and V max1 represent apparent a‹nity constant and apparent maximum formation activity of metabolites for high-a‹nity components, and K m2 and V max2 represent apparent a‹nity constant and apparent maximum formation activity of metabolites for low-a‹nity components. CL int of NE-098 and NE-152＋163mix formations in the liver were calculated as the sum of the ratio of V max to K m in the high-and low a‹nity components based on two enzyme model. For NE-100 metabolism in intenstine, K m and V max represent apparent a‹nity component and apparent maximum formation activity of metabolites. CL int in intestine was calculated as the ratio of V max to K m . -: Not detected. Correlation coe‹cient was shown as r 2 value. *: pº0.0001. NE-100 (1 mM) was incubated with human liver microsomal samples (n＝28).
examined, NE-098 and NE-125 formation activities signiˆcantly correlated with activities of testosterone 6 b-hydroxylation (r 2 ＝0.680) and dextromethorphan O-demethylation (r 2 ＝0.826), respectively, at 1 mM NE-100. NE-152＋163mix formation activity signiˆcantly correlated with both activities of dextromethorphan O-demethylation and testosterone 6 bhydroxylation (r 2 ＝0.811, and 0.474, respectively). Immunoinhibition study by HLM and HIM: The inhibitory eŠect of anti-CYP2D6 and anti-CYP3A4 antibodies on the formation of each metabolite are shown in Fig. 3 (A)¿(C) at three substrate concentrations (0.1, 1 and 10 mM) in HLM. At 0.1 mM NE-100 (which is corresponding to a Km1 value of a high-a‹nity component), the anti-CYP2D6 antibody inhibited the NE-098, NE-152＋163mix and NE-125 formations by 17.5z, 90.8z and 93.2z, respectively. The inhibitory eŠect of anti-CYP2D6 antibody on NE-125 formation did not diŠer among these three concentrations of NE-100. However, the inhibitory eŠect on NE-152＋ 163mix formation changed depending on concentration of the substrate. The inhibitory eŠect on NE-098 formation also changed depending on the concentration but was less than that seen with NE-152＋163mix formation. On the other hand, the anti-CYP3A4 antibody inhibited the NE-098 formation at 0.1 mM NE-100 by 42.5z, but weakly inhibited NE-152＋163mix and NE-125 formations. Depending on increase in the substrate concentration, the anti-CYP3A4 antibody inhibited the formation activity of NE-152＋163mix as well as NE-098.
The inhibitory eŠects of anti-CYP3A4 antibody and anti-CYP2C13 serum on NE-098 and NE-152＋163mix formations in HIM are shown in Fig. 4 . The antiserum raised against CYP2C13 cross-reacts with CYP2C8, 2C9 and 2C19 (the data sheet provided by the manufacturers). Anti-CYP3A4 antibody inhibited the NE-098 formation at 10 and 200 mM NE-100 by 71.6z and 45.0z, respectively. Anti-CYP2C13 serum inhibited it at both concentrations by 16.2z and 14.3z, respectively. Similarly, an anti-CYP3A4 antibody inhibited the NE-152＋163mix formation at 10 and 200 mM NE-100 by 71.7z and 69.6z, respectively. Anti-CYP2C13 serum inhibited it at both concentrations by 6.7z and 18.8z, respectively.
Chemical inhibition study in HLM and HIM: The eŠects of selective CYP inhibitors on the formation activities of NE-098, NE-152＋163mix and NE-125 in HLM were examined at two substrate concentrations (0.1 mM and 10 mM). As shown in Fig. 5 , 100 mM SKF-525A (non-selective CYP inhibitor) completely inhibited all metabolite formations at a 0.1 mM substrate concentration. At the low substrate concentration (0.1 mM corresponding to Km1 value of a high-a‹nity component), the formation activity of NE-098 was inhibited by 48.2 z and 35.2z by ketoconzole and troleandomycin (selective CYP3A4 inhibitors), respectively, and was inhibited by 22.5z by quinidine (a selective CYP2D6 inhibitor). On the other hand, the formation activity of NE-152＋163mix was strongly inhibited by quinidine and was weakly inhibited by ketoconazole and troleandomycin. The formation activity of NE-125 was clearly inhibited by quinidine.
At a high substrate concentration (10 mM corresponding to the K m2 value of a low-a‹nity component), the formation activity of NE-098 was strongly inhibited by 78.8z and 49.7z by ketoconazole and troleandomycin, respectively, and the inhibitory percentage was much greater than those that at the low substrate concentration. Furthermore, the formation activity of NE-098 was slightly inhibited by sulfaphenazole (a selective CYP2C9 inhibitor) and S-mephenytoin (a substrate of CYP2C19). By contrast to a low concentration, the formation activity of NE-152＋163mix at the high substrate concentration was mainly reduced by ketoconazole and troleandomycin, but not by quinidine. The formation activity of NE-125 at a high substrate concentration was not signiˆcantly inhibited by typical CYP inhibitors used in this study.
EŠects of selective CYP inhibitors on NE-098 and NE-152＋163mix formations in HIM were also evaluated at 0.2, 10 and 200 mM substrate concentrations. Ketoconazole strongly inhibited the formation activity of NE-098 by 88.3z, 86.3z and 81.2z at 0.2, 10 and 200 mM NE-100, respectively. For other inhibitors, sulfaphenazole and lansoprazole (for CYP2C19, 2 mM) inhibited the formation activity of NE-098 at 10 mM NE-100 by 6.6z and 9.5z, respectively. The formation activity of NE-152＋163mix at 0.2 mM, 10 mM and 200 mM NE-100 was also inhibited by ketoconazole and the inhibitory rates were 46.6z, 84.1z and 71.0z, respectively. Although arachidonic acid (for CYP2J2, 100 mM) inhibited the NE-152＋163mix formation at 0.2, 10 and 200 mM NE-100 by 38.4z, 43.2z and 24z, Kinetic studies on the formation of NE-098, NE-152＋163mix and NE-125 in the recombinant human P450s (CYP2C9-Arg, 2D6-Val, and 3A4) were done using with substrate concentration from 0.05 to 20.0 mM. For CYP1A2 and CYP2C19, the kinetic parameters were estimated using the results obtained from a preliminary study on microsomal protein concentration. K m and V max values in recombinant CYPs were determined with Eadie-Hofstee plots. CL int.cDNA-CYP-X was calculated ratio of V max to K m . Predicted CL int.HLM-CYP-X was calculated from kinetic parameters on recombinant CYPs using RAF approaches, as described on Materials and Methods. For NE-098 formation, the predicted CL int.HLM-total ＝CL int. In this study, RAF values for each CYP form were calculated based on the ratio of the activity for a relatively speciˆc reaction in HLM (H161) divided by the activity for that same reaction in recombinant CYP. The speciˆc activity for each CYP form used for calculating the RAF values has been described in the data sheet supplied by the manufacturer.
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Kinetic study of NE-100 metabolism by recombinant human cytochrome P450: Kinetic parameters (K m , Vmax and CLint.cDNA-CYP-X) for NE-098, NE-152＋163 and NE-125 formations are shown in Table 3 and CLint.HLM-CYP-X was extrapolated to human liver activity, using the RAF approach. NE-098 was produced in all the recombinant CYP forms used. Among all recombinant CYP forms studied, CYP2D6 showed the smallest Km value and the largest CLint.cDNA-CYP value for NE-098 formation (0.10 mM and 0.405 mLW min W mg protein). CLint.cDNA-CYP2D6 was approximately 40 fold greater than CL int.cDNA-CYP for CYP3A4 or CYP2C9, whereas the predicted CLint.HLM-CYPx of CYP2D6, CYP3A4 and CYP2C9 normalized to human liver activity was 0.065, 0.046 and 0.011 mL W min W mg protein, respectively.
The NE-152＋163mix formation was observed in recombinant CYP2D6 and CYP3A4. Km values for CYP2D6 and CYP3A4 were 0.07 mM and 9.78 mM, respectively. There data clearly support the proposal that CYP2D6 is a high-a‹nity enzyme and CYP3A4 is a low-a‹nity enzyme for this metabolic pathway. The NE-125 formation was observed in recombinant CYP2D6, CYP2C9 and CYP2C19, but activities in CYP2C9 and CYP2C19 were very low compared with activities for CYP2D6. Km values for CYP2D6, CYP2C9 and CYP2C19 were 0.06, 23.62 and 144.90 mM, respectively.
Relative contribution rate of CYP forms to the formation activity of metabolites in human liver microsomes: As shown in Table 3 and Fig. 6 , predicted CLint-HLM-total values for each metabolite were 0.126 (for NE-098 formation), 0.201 (for NE-152＋163mix formation) and 0.342 mL W min W mg protein (for NE-125 formation) and agreed well with data on HLM. As described under Materials and Methods, the contribution rates of CYP2D6, CYP3A4, CYP2C9, CYP2C19 and CYP1A2 to NE-098 formation were estimated to be 51.9z, 36.5z, 8.8z, 1.4z and 1.4z, respectively and the contribution rates of CYP2D6 and CYP3A4 to NE-152＋163mix formation were estimated to be 95.6z and 4.4z, respectively. Moreover, the NE-125 forma- Fig. 6 . Hepatic intrinsic clearance and relative contribution for each metabolite formation in pooled HLM. The clearance was calculated by extrapolating in vitro kinetic data with recombinant CYP forms to human liver activity using a RAF approach. Predicted CL int.HLM-CYP-X was calculated from kinetic parameters on recombinant CYPs using RAF approach as described under Materials and Methods. The RAF values for each CYP form were calculated as the ratio of the speciˆc activities described in the data sheet supplied by the manufacturer in HLM and recombinant CYPs microsomes. Figure 6 (C) represents the expanded ranges from concentrations near 0 mM (S9K m ) to 1 mM. The contribution rate of the formation of each metabolite for the entire metabolism of NE-100 is estimated based on the ratio of formation activity for each metabolite to sum of activities of NE-125, NE-152＋163mix and NE-098 at each substrate concentration.
tion, which showed the largest activity among the primary metabolites, is likely to be mostly mediated by CYP2D6. At an NE-100 concentration corresponding to a patient plasma level (Km:S), the contribution rate of CYP2D6 was 99.8z of the total metabolism, while rates of other forms were negligible.
Discussion
To clarify NE-100 metabolism in humans, CYP forms were identiˆed. In our pervious data, NE-100 metabolism was shown to be mediated by CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. However, CYP2D6 and CYP3A4 were predominant forms involved in NE-100 metabolism in the liver and in the small intestine, respectively.
3) These data support the possibility that NE-100 receives the considerableˆrst pass eŠect in the small intestine. In the previous study, however, we were unable to quantify individual metabolites and metabolism of NE-100 was monitored by substrate disappearance. For further elucidation, we identied metabolites and predicted the contribution of CYP forms for theˆrst pass eŠect in liver and small intestine.
Four primary metabolites (NE-098, NE-125, NE-152 and NE-163) were detected in reaction mixtures, including liver microsomes (Fig. 1) . Judging from inhibition studies with antibodies against CYP forms (Fig. 3) and typical CYP inhibitor (Fig. 5) , at a low NE-100 concentration (0.1 mM), all metabolites were predominantly catalyzed by CYP2D6. Thisˆnding supports our previous data 3) for which the disappearance of NE-100 was measured. On the other hand, at a high NE-100 concentration, kinetic data on individual metabolites diŠered Figure 7 (B and D) was shown as expanded to ranges from concentrations near 0 mM (S9K m ) to 1 mM. The contribution rate of CYP forms on the formation of each metabolite is estimated, as described under Materials and Methods.
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Contribution of CYPs to NE-100 Metabolism from the previous data. 3) NE-125 formation is predominantly catalyzed by CYP2D6 and NE-098 and NE-152＋163mix formations are catalyzed by CYP3A4, CYP2C9 and CYP2D6 in HLM. These results were supported by data on kinetic and recombinant CYP studies ( Table 3) . The NE-125 formation displayed a monophasic curve in Eadie-Hofstee plots, although NE-098 and NE-152＋163mix formations displayed biphasic curves (Fig. 2) . Together with these data, the contribution rate of individual CYP forms might change in humans depending on NE-100 concentrations. In this study, although we assumed the formation of NE-152 and NE-163 to be the mixture of two metabolites, diŠerent CYP forms might be involved in formations of NE-152 and NE-163, respectively.
The contributions of the CYP form involved in the formation of NE-100 metabolites in HLM have been estimated using RAF approaches. [19] [20] [21] [22] [23] [24] The contribution rates of CYP forms to the formation of each metabolite in HLM were predicted using the kinetic parameter (Km, Vmax) with recombinant CYP forms and RAF values. The predicted change in contribution rates of CYP forms for individual metabolites is shown in Fig. 7 . At the NE-100 concentration corresponding to in vivo conditions, the NE-125 and NE-152＋163mix formations were predominantly catalyzed by CYP2D6 (Fig. 7(E) and 7(F) ). In contrast, multiple CYP forms appear to contribute to the NE-098 formation ( Fig. 7(C) ). At the high substrate concentration, although the activity of NE-125 formation is low compared with activities of other metabolites, CYP2D6 is also a major form for NE-125 formation. Even when the NE-100 concentration was increased to 10 mM, the contribution rates of CYP2D6, CYP2C9 and CYP2C19 for the NE-125 formation were predicted to be 81.2z, 15.2z and 3.6z, respectively. The rates for the NE-152 ＋163mix formation decreased in CYP2D6 and it increased in CYP3A4, depending on the increase in NE-100 concentrations. Similar results were also observed regarding NE-098 formation. Theseˆndings support results obtained in chemical inhibition studies and suggest that major CYP forms involved in NE-100 metabolism diŠer between the low and high substrate concentrations. As shown in Fig. 7((A) and (B) ), the contribution rate of CYP2D6 to the entire metabolism of NE-100 in HLM was large in case of a low substrate concentration, but the rate of CYP3A4 was large at a high substrate concentration. Thus, the multiple metabolites are formed at a low concentration, however at a high concentration, NE-098 is a major metabolite (Fig. 6(B) and (C) ). We reported that the CYP form catalyzing N-demethylation of diazepam predominantly depended on the drug concentration and we suggested that the concentration used is most critical for in vitro metabolic studies. [25] [26] [27] Thus, estimation of the contributions of CYP forms and determination of major metabolites at low and high substrate concentrations are important for considerations between pharmacokinetics and toxicicokinetics, drug-drug interactions or the polymorphism of certain enzymes.
On the other hand, in our previous kinetic study, we suggested that NE-100 disappearance in HIM was predominantly mediated by CYP3A4 and that the largê rst pass eŠect on NE-100 might occur in the small intestine after oral administration.
3) As shown in the present study, NE-100 was mainly metabolized into NE-098 and NE-152＋163mix, but not into NE-125 in HIM ( Table 1 and Fig. 2) . Based on the inhibition study (Fig. 4) , these metabolizing reactions were predominantly mediated by CYP3A4, although CYP2C19 and CYP2J2 seem to be partially involved in formations of these metabolites in HIM. There results also suggest that a signiˆcant amount of CYP2D6 is not expressed in small intestine. When the intrinsic clearance was compared between liver and the small intestine, CL int-HIM was 3.2 times and 14.9 times smaller than for CLint-HLM in the NE-098 and NE-152＋163mix formation. In addition, NE-125, a major metabolite in the HLM, was not formed in the HIM. Thus, the contributions of intestinal metabolism for theˆrst pass eŠect are likely to be less than those for hepatic metabolism.
Due to the high contribution rate of CYP2D6 for metabolism in the liver, the metabolism of NE-100 might be inhibited by drugs that are metabolized by CYP2D6 such as beta-blockers, tricyclic antidepressants antiarrhythmic and antipsychotic drugs in livers. [28] [29] [30] In addition, large inter-individual diŠerences in plasma concentrations of NE-100 may occur between an extensive metabolizer and a poor metabolizer of CYP2D6. Therefore estimation of contribution rates of CYP forms involved in drug metabolism is very important to consider the relationship between plasma concentration and e‹cacy or side eŠects.
In conclusion, four primary metabolites (NE-098, NE-125, NE-152 and NE-163) and CYP forms involved in NE-100 metabolism were identiˆed. All these metabolites were mainly catalyzed by CYP2D6, at a substrate concentration assuming plasma level of NE-100 in a patient (Km:S) in the human liver. At high NE-100 concentrations, however, the contribution of CYP3A4 for NE-098 and NE-152＋163mix formations increased. In the small intestine, NE-100 was mainly metabolized to NE-098 by CYP3A4, but the extent seemed to be less than that for the liver. Considering the entire metabolism of NE-100, the present study showed that the metabolism in the liver signiˆcantly contributed to the biotransformation of NE-100, compared to the intestinal metabolism.
